Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
Optinose US Inc.
Study ID
NCT06850805
Phase
PHASE3
Status
Recruiting

Conditions

  • Chronic Rhinosinusitis Without Nasal Polyps

Eligibility Criteria

Sex
ALL
Age
12 Years - 17 Years
Healthy Volunteers
Not accepted

Interventions

  • OPN-375 — DRUG
    OPN-375 (fluticasone propionate) delivered via exhalation delivery system (EDS) BID
  • Placebo — DRUG
    Placebo solution administered via exhalation delivery system (EDS).

Study Details

This is a 12-Week randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of intranasal administration of 186 µg of OPN-375 twice a day (BID) in adolescent subjects with chronic rhinosinusitis without nasal polyps. The total planned number of subjects is approximately 84 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 1:1 ratio (OPN-375 186 µg:placebo). The study includes a PK sub-study, in which up 14 subjects will be enrolled to obtain 10 completers.

Key Dates

Start date
Jul 28, 2025
Status verified
Mar 2026
Primary completion
Mar 31, 2028
Completion
Oct 31, 2028

Study Design

Enrollment
84 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Placebo BID
    Double-Blind Treatment Phase: Intranasal administration of matching placebo BID x 12 weeks
  • Active Comparator: OPN-375 186 µg BID
    Double-Blind Treatment Phase: Intranasal administration of OPN-375 186 µg x 12 weeks

Primary Outcome Measure

Change from baseline to the end of Week 4 in the average instantaneous CSS (evaluation of symptom severity immediately preceding the time of scoring). [ Time Frame: 4 Weeks ]

Central Contacts

Locations (21)

FacilityCityStateZIPSite coordinators
San Tan Allergy & AsthmaGilbertArizona85214-
Children's Hospital of Orange CountyOrangeCalifornia92868
Jenny Vo
714-509-4254
Jay Bhatt, MD (PRINCIPAL_INVESTIGATOR)
DaVinci Research, LLCSacramentoCalifornia95661
Rose Khalatyan
916-531-2788
Randall Ow, MD (PRINCIPAL_INVESTIGATOR)
Breathe Clear InstituteTorranceCalifornia90503
Ryan Dudley
323-725-0657
Steven Davis, MD (PRINCIPAL_INVESTIGATOR)
Children's Hospital ColoradoAuroraColorado80045
Paul Hynes
720-777-3570
Sarah Gitomer, MD (PRINCIPAL_INVESTIGATOR)
Colorado ENT & AllergyColorado SpringsColorado80909
Monica Davis
719-867-7804
Bryan Davis, MD (PRINCIPAL_INVESTIGATOR)
Children's Healthcare of AtlantaAtlantaGeorgia30329
Katelyn Abeln
404-785-7529
India Taliaferro
404-785-0534
Kenneth Kennedy, MD (PRINCIPAL_INVESTIGATOR)
Southern Illinois University School of MedicineSpringfieldIllinois62702
Alaine Nixon
217-545-8065
Dana Crosby, MD (PRINCIPAL_INVESTIGATOR)
Kentuckiana ENTLouisvilleKentucky40205
Wendi Miller
502-894-8441
Thomas Higgins, MD (PRINCIPAL_INVESTIGATOR)
Centers for Advanced ENT CareTowsonMaryland21204
Holly Stadden
410-821-5151
Douglas Reh, MD (PRINCIPAL_INVESTIGATOR)
University of Missouri Medical CenterColumbiaMissouri65212
Rebecca Schneider
573-882-2549
Christine Franzese, MD (PRINCIPAL_INVESTIGATOR)
University of Rochester Medical CenterRochesterNew York14642
Paul Allen
585-275-1186
Li-Xing Man, MD (PRINCIPAL_INVESTIGATOR)
Allergy, Asthma and Clinical Research CenterOklahoma CityOklahoma73120
Nasir Ali, MD
405-286-9431
Martha Tarpay, MD (PRINCIPAL_INVESTIGATOR)
Vital Prospects Clinical Research InstituteTulsaOklahoma74136
Riley Pritzlaff
918-392-4550
Iftikhar Hussain, MD (PRINCIPAL_INVESTIGATOR)
Charleston ENT & AllergyNorth CharlestonSouth Carolina29414
John Stavrinakis
843-654-8884
Thomas Murphy, MD (PRINCIPAL_INVESTIGATOR)
Carolina ENT Clinic/CENTRI Inc.OrangeburgSouth Carolina29118
Simone Ansley
803-536-5511
John Ansley, MD (PRINCIPAL_INVESTIGATOR)
Orion Clinical ResearchAustinTexas78759
Stephanie Nunnelee
512-492-3799
William Howland, III, MD (PRINCIPAL_INVESTIGATOR)
Alamo ENT AssociatesSan AntonioTexas78258
Maxine Mata
210-545-0404
Jeffrey Rosenbloom, MD (PRINCIPAL_INVESTIGATOR)
STAAMP ResearchSan AntonioTexas78229
Dario Rocha
210-614-6673
Erika Gonzalez, MD (PRINCIPAL_INVESTIGATOR)
University of UtahSalt Lake CityUtah84112
Martin Carricaburu
801-581-3363
Jill Jeffe, MD (PRINCIPAL_INVESTIGATOR)
EVMS at Old Dominion UniversityNorfolkVirginia23507
Laura Stone
757-388-6238
Kent Lam, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Gilbert, AZ

Related Studies